Investors Had One Helluva Week
Insights - It was a reckless day, with securities across the board halted by circuit-breakers, and some discount brokers having difficulty even placing orders.
Read NowInsights
GlaxoSmithKline Isn’t Buying Tekmira for its Ebola Drug
Insights - Ebola stocks are still in vogue, though for new reasons on Thursday. The DailyMail reported on Wednesday evening that up to four drug companies, including Shire … Continue Reading
Read Now
EnteroMedics Reports New Data as Company Awaits FDA Approval
Insights - Three-year results from EnteroMedics’ (ETRM) DM2 ENABLE Study, a small trial of the company’s VBLOC vagal blocking therapy (delivered via the Maestro System), indicate some positive outcomes in … Continue Reading
Read Now
Kite Pharma Gets a Lift on Blood Cancer Trial
Insights - 12 out of 13 patients receiving an experimental treatment for blood cancer from Kite Pharma (KITE) experienced a response to the treatment, the company said in … Continue Reading
Read Now
Regado Stops Trial of its Only Real Asset
Insights - Regado Biosciences (RGDO) has halted permanently a 13,000-patient phase 3 trial of Revolixys Kit, its two-component anticoagulant system, after serious allergic reactions were seen in the first 3,200 … Continue Reading
Read Now
Auxilium’s Xiaflex Makes Butts Look Good in Midstage Study
Insights - Auxilium's (AUXL) Xiaflex improves cellulite appearance in a phase 2a, 150-women study.
Read Now
Ampio Hopes to Broaden FDA Label with Newest Ampion Data
Insights - A small and open-label study of Ampio Pharmaceuticals’ (AMPE) AMPION given in multiple injections demonstrated positive results at 6-weeks, said Ampio on Monday morning, producing pain reduction … Continue Reading
Read Now